MARÍA ISABEL
BLANCAS LÓPEZ-BARAJAS
PROFESORA ASOCIADA LABORAL
Institute Catalá Oncología
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Institute Catalá Oncología (6)
2024
2023
-
Correction to: SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2665-2678), 10.1007/s12094-023-03203-8)
Clinical and Translational Oncology
-
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study
The Lancet Oncology, Vol. 24, Núm. 9, pp. 1029-1041
-
SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)
Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2665-2678
2019
-
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study
Breast Cancer Research and Treatment, Vol. 177, Núm. 1, pp. 115-125
-
Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens
Clinical and Translational Oncology, Vol. 21, Núm. 4, pp. 459-466